An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Florence Ader, Marion Noret, François-Xavier Lescure et al.|Clinical Microbiology and Infection|2021Cited by 107
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trialFlorence Ader, Marion Noret, Nathan Peiffer‐Smadja et al.|medRxiv|2021Cited by 15
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy TrialVida Terzić, Kévin Bouiller, Joe Miantezila Basilua et al.|Clinical Infectious Diseases|2024Cited by 14
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trialDavid M. Smadja, France Mentré, Clément Massonnaud et al.|Scientific Reports|2025Cited by 7
An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trialFlorence Ader, Marion Noret, Nathan Peiffer‐Smadja et al.|medRxiv|2022Cited by 1